MedCity News | Keryx's chronic kidney disease drug shows reduction in serum phosphorus MedCity News (Reuters) - Keryx Biopharmaceuticals Inc said its kidney drug met the main goals of a mid-stage study in patients with chronic kidney disease who were not on dialysis. Shares of the company rose about 16 percent to $12.84 in premarket trading. The drug ... Keryx says kidney drug effective; shares hit seven-year high Keryx Says Kidney Disease Drug Zerenex Worked Why Keryx Shares Skyrocketed |
